An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine

Molecular BioSystems

Volumn 10, Issue 8, 2014, Pages 2215-2228

  Bhakat, Soumendranath ^a   Martin, Alberto J M ^b,c   Soliman, Mahmoud E S ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Fundacion Ciencia para la Vida   (Chile)

^c UNIVERSIDAD DE VALPARAÍSO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; METHIONINE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE; VALINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; BIOLOGY; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR DYNAMICS; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROTEIN SECONDARY STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; LAMIVUDINE; METHIONINE; MOLECULAR DYNAMICS SIMULATION; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN STRUCTURE, SECONDARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VALINE;

EID: 84903757923     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/c4mb00253a     Document Type: Article

References (44)

1. E. U. Morah Are People Aware of Their HIV-positive Status Responsible for Driving the Epidemic in Sub-Saharan Africa? The Case of Malawi Dev. Policy Rev. 2007 25 215 242
2. S. Broder The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic Antiviral Res. 2010 85 1 18
3. B. Young Review: mixing new cocktails: drug interactions in antiretroviral regimens AIDS Patient Care ST. 2005 19 286 297
4. T. Cihlar A. S. Ray Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine Antiviral Res. 2010 85 39 58
5. M.-P. de Bethune Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009) Antiviral Res. 2010 85 75 90
6. J. D. Meteer R. F. Schinazi J. W. Mellors N. Sluis-Cremer Molecular mechanism of HIV-1 resistance to 3′-azido-2′,3′- dideoxyguanosine Antiviral Res. 2014 101 62 67
7. K. Diallo M. Gotte M. A. Wainberg Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 2003 47 3377 3383
8. J. E. Gallant The M184V mutation: what it does, how to prevent it, and what to do with it when it's there AIDS Read. 2006 16 556 559
9. J. M. J. Alvir J. A. Lieberman A. Z. Safferman J. L. Schwimmer J. A. Schaaf Clozapine-induced agranulocytosis-Incidence and risk-factors in the United-States N. Engl. J. Med. 1993 329 162 167
10. H. Choo Y. H. Chong C. K. Chu The role of 2′,3′-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V) Bioorg. Med. Chem. Lett. 2003 13 1993 1996
11. S. G. Sarafianos K. Das A. D. Clark J. P. Ding P. L. Boyer S. H. Hughes E. Arnold Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids Proc. Natl. Acad. Sci. U. S. A. 1999 96 10027 10032
12. P. L. Boyer S. G. Sarafianos E. Arnold S. H. Hughes The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1 J. Virol. 2002 76 3248 3256
13. S. M. Ahmed H. G. Kruger T. Govender G. E. M. Maguire Y. Sayed M. A. A. Ibrahim P. Naicker M. E. S. Soliman Comparison of the Molecular Dynamics and Calculated Binding Free Energies for Nine FDA-Approved HIV-1 PR Drugs Against Subtype B and C-SA HIV PR Chem. Biol. Drug Des. 2013 81 208 218
14. D. E. Elmore D. A. Dougherty Molecular dynamics simulations of wild-type and mutant forms of the Mycobacterium tuberculosis MscL channel Biophys. J. 2001 81 1345 1359
15. M. L. Barreca K. W. Lee A. Chimirri J. M. Briggs Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: Mechanism for inhibition and drug resistance Biophys. J. 2003 84 1450 1463
16. E. El-Bastawissy M. H. Knaggs I. H. Gilbert Molecular dynamics simulations of wild-type and point mutation human prion protein at normal and elevated temperature J. Mol. Graphics Modell. 2001 20 145 154
17. H. Wan J.-p. Hu X.-h. Tian S. Chang Molecular dynamics simulations of wild type and mutants of human complement receptor 2 complexed with C3d Phys. Chem. Chem. Phys. 2013 15 1241 1251
18. X. Chen S. Zhu S. Wang D. Yang J. Zhang Molecular dynamics study on the stability of wild-type and the R220K mutant of human prion protein Mol. Simul. 2014 40 504 513
19. R.-X. Gu L. A. Liu Y.-H. Wang Q. Xu D.-Q. Wei Structural Comparison of the Wild-Type and Drug-Resistant Mutants of the Influenza A M2 Proton Channel by Molecular Dynamics Simulations J. Phys. Chem. B 2013 117 6042 6051
20. C. C. David and D. J. Jacobs, Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins, in Protein Dynamics: Methods and Protocols, ed., D. R. Livesay, 2014, pp. 193-226
21. A. Amadei A. B. M. Linssen B. L. de Groot D. M. F. van Aalten H. J. C. Berendsen An efficient method for sampling the essential subspace of proteins J. Biomol. Struct. Dyn. 1996 13 615 625
22. I. Daidone A. Amadei Essential dynamics: foundation and applications Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2012 2 762 770
23. E. Laine I. C. de Beauchêne D. Perahia C. Auclair L. Tchertanov Mutation D816V Alters the Internal Structure and Dynamics of c-KIT Receptor Cytoplasmic Region: Implications for Dimerization and Activation Mechanisms PLoS Comput. Biol. 2011 7 e1002068 10.1371/journal.pcbi.1002068
24. A. J. M. Martin M. Vidotto F. Boscariol T. Di Domenico I. Walsh S. C. E. Tosatto RING: networking interacting residues, evolutionary information and energetics in protein structures Bioinformatics 2011 27 2003 2005
25. H. F. Huang R. Chopra G. L. Verdine S. C. Harrison Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: Implications for drug resistance Science 1998 282 1669 1675
26. E. F. Pettersen T. D. Goddard C. C. Huang G. S. Couch D. M. Greenblatt E. C. Meng T. E. Ferrin UCSF chimera-A visualization system for exploratory research and analysis J. Comput. Chem. 2004 25 1605 1612
27. A. W. Goetz M. J. Williamson D. Xu D. Poole S. Le Grand R. C. Walker Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born J. Chem. Theory Comput. 2012 8 1542 1555
28. S. E. Palmer R. M. McLean P. M. Ellis M. Harrison-Woolrych Life-threatening clozapine-induced gastrointestinal hypomotility: An analysis of 102 cases J. Clin. Psychiatry 2008 69 759 768
29. P. Cieplak W. D. Cornell C. Bayly P. A. Kollman Application of the multimolecule and multiconformational RESP methodology to biopolymers-Charge derivation for DNA, RNA, and proteins J. Comput. Chem. 1995 16 1357 1377
30. J. M. Wang R. M. Wolf J. W. Caldwell P. A. Kollman D. A. Case Development and testing of a general amber force field J. Comput. Chem. 2004 25 1157 1174
31. K. Lindorff-Larsen S. Piana K. Palmo P. Maragakis J. L. Klepeis R. O. Dror D. E. Shaw Improved side-chain torsion potentials for the Amber ff99SB protein force field Proteins: Struct., Funct., Bioinf. 2010 78 1950 1958
32. W. L. Jorgensen J. Chandrasekhar J. D. Madura R. W. Impey M. L. Klein Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983 79 926 935
33. M. J. Harvey G. De Fabritiis An Implementation of the Smooth Particle Mesh Ewald Method on GPU Hardware J. Chem. Theory Comput. 2009 5 2371 2377
34. J.-P. Ryckaert G. Ciccotti H. J. C. Berendsen Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 1977 23 327 341
35. S. Le Grand A. W. Goetz R. C. Walker SPFP: Speed without compromise-A mixed precision model for GPU accelerated molecular dynamics simulations Comput. Phys. Commun. 2013 184 374 380
36. P. A. Kollman I. Massova C. Reyes B. Kuhn S. H. Huo L. Chong M. Lee T. Lee Y. Duan W. Wang O. Donini P. Cieplak J. Srinivasan D. A. Case T. E. Cheatham Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models Acc. Chem. Res. 2000 33 889 897
37. I. Massova P. A. Kollman Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding Perspect. Drug Discovery Des. 2000 18 113 135
38. V. Tsui D. A. Case Theory and applications of the generalized Born solvation model in macromolecular Simulations Biopolymers 2001 56 275 291
39. W. Humphrey A. Dalke K. Schulten VMD: Visual molecular dynamics J. Mol. Graphics Modell. 1996 14 33 38
40. A. Bakan L. M. Meireles I. Bahar ProDy: Protein Dynamics Inferred from Theory and Experiments Bioinformatics 2011 27 1575 1577
41. J. M. Word S. C. Lovell T. H. LaBean H. C. Taylor M. E. Zalis B. K. Presley J. S. Richardson D. C. Richardson Visualizing and quantifying molecular goodness-of-fit: Small-probe contact dots with explicit hydrogen atoms J. Mol. Biol. 1999 285 1711 1733
42. N. T. Doncheva K. Klein F. S. Domingues M. Albrecht Analyzing and visualizing residue networks of protein structures Trends Biochem. Sci. 2011 36 179 182
43. P. Shannon A. Markiel O. Ozier N. S. Baliga J. T. Wang D. Ramage N. Amin B. Schwikowski T. Ideker Cytoscape: A software environment for integrated models of biomolecular interaction networks Genome Res. 2003 13 2498 2504
44. C. George Priya Doss B. Rajith C. Chakraboty V. Balaji R. Magesh B. Gowthami S. Menon M. Swati M. Trivedi J. Paul R. Vasan M. Das In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach Mol. BioSyst. 2014 10 421 436